期刊
BIOCHEMICAL PHARMACOLOGY
卷 195, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2021.114849
关键词
Parkinson 's disease; Dopamine; Stem cell therapy; Nucleic acid therapy; Nanomedicine; Nose-to-brain delivery; Viral vector-mediated delivery
资金
- Deanship of Scientific Research (DSR) at King Abdulaziz Uni-versity, Jeddah, Saudi Arabia [FP-019-43]
Parkinson's disease is a progressive neurodegenerative disorder primarily affecting the elderly population. Despite the challenges in management, extensive research has been conducted in the past two decades to explore novel therapeutic approaches, including the use of nanotechnology to enhance drug bioavailability. The main limitations of existing therapeutic interventions are low efficacy and associated side effects.
Parkinson disease (PD) is a progressive neurodegenerative disorder prevalent mainly in geriatric population. While, L-DOPA remains one of the major choices for the therapeutic management of PD, various motor and nonmotor manifestations complicate the management of PD. In the last two decades, exhaustive research has been carried out to explore novel therapeutic approaches for mitigating motor and non-motor symptoms of PD. These approaches majorly include receptor-based, anti-inflammatory, stem-cell and nucleic acid based. The major limitations of existing therapeutic interventions (of commonly oral route) are low efficacy due to low brain bioavailability and associated side effects. Nanotechnology has been exploited and has gained wide attention in the recent years as an approach for enhancement of bioavailability of various small molecule drugs in the brain. To address the challenges associated with PD therapy, nose-to-brain delivery utilizing nanomedicine-based approaches has been found to be encouraging in published evidence. Therefore, the present work summarises the major challenges and limitations with antiparkinsonian drugs, novel therapeutic interventions, and scope of nanomedicine-based nose-to-brain delivery in addressing the current challenges of antiparkinsonian therapy. The manuscript tries to sensitize the researchers for designing brain-targeted nanomedicine loaded with natural/ synthetic scaffolds, biosimilars, and nucleic acids that can bypass the first-pass effect for the effective management of PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据